surmount trial tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 SURMOUNT-1 (NEJM 2022) tested tirzepatide

Orders Ship in 72 Hours* *Mon - Thursday Overnight Shipping (Not on Weekends) Tirzepatide, a dual GIP and GLP-1 receptor agonist, helps control hunger by making you feel full longer after eating less, and also supports insulin release with additional metabolic benefits

In these trials, MOUNJARO was studied as monotherapy (SURPASS-1)

Khoo J, Hsiang JC, Taneja R, et al

Standard-dose compounded tirzepatide is designed for patients who may benefit from a stronger dual-pathway approach

Whatever the upfront costs may be, scientists stress the importance of addressing obesity

[DOI] [PubMed] [Google Scholar] 97.Lorenz M., Pfeiffer C., Steinstrsser A., et al